Literature DB >> 33402103

The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis.

Masoumeh Moslemi1, Yousef Moradi2, Hojat Dehghanbanadaki3, Hamed Afkhami4, Mansoor Khaledi4, Najmeh Sedighimehr5, Javad Fathi6, Ehsan Sohrabi7.   

Abstract

BACKGROUND: Ataxia telangiectasia-mutated (ATM) gene contributes to repair damaged DNA and to regulate cell cycle; therefore, ATM variants seem to increase breast cancer risk; however, the results are controversial. So we conducted a systematic review and meta-analysis to clarify the pooled association between various ATM variants and the risk of breast cancer.
METHODS: The relevant studies were searched through Scopus, Web of Science, PubMed and Cochrane. Stratified and subgroup analyses were performed to explore heterogeneity between studies and assess effects of study quality. The pooled estimates logarithm with standard error logarithm of odds ratio and relative risk with confidence interval were calculated.
RESULTS: This study revealed that there is association between ATM variants and the risk of breast cancer; according to the seven adjusted case-control studies, OR of this association was estimated as 1.67 (95%CI: 0.73-3.82), according to nine unadjusted case-control studies, the crude OR was 2.27 (95% CI: 1.17-4.40) and according to two cohorts, the RR was estimated as 1.68 (95% CI: 1.17-2.40).
CONCLUSIONS: The ATM variants are associated with an increased risk of breast cancer that ATM V2424G mutation is detected as the most predisposing factor while ATM D1853V, L546V, and S707P variants have the least predictive ability.

Entities:  

Keywords:  ATM; Breast cancer; Meta-analysis; Systematic review; Variant

Mesh:

Substances:

Year:  2021        PMID: 33402103      PMCID: PMC7786920          DOI: 10.1186/s12885-020-07749-6

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  38 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways.

Authors:  Robert T Abraham
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

3.  A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer.

Authors:  Natalia Bogdanova; Cezary Cybulski; Marina Bermisheva; Ihor Datsyuk; Paria Yamini; Peter Hillemanns; Natalja Nikolaevna Antonenkova; Elza Khusnutdinova; Jan Lubinski; Thilo Dörk
Journal:  Breast Cancer Res Treat       Date:  2008-09-21       Impact factor: 4.872

4.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Authors:  A Broeks; J H Urbanus; A N Floore; E C Dahler; J G Klijn; E J Rutgers; P Devilee; N S Russell; F E van Leeuwen; L J van 't Veer
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

5.  Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.

Authors:  Ariel E Hirsch; David P Atencio; Barry S Rosenstein
Journal:  Breast Cancer Res Treat       Date:  2007-02-27       Impact factor: 4.872

Review 6.  Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations.

Authors:  R A Gatti; A Tward; P Concannon
Journal:  Mol Genet Metab       Date:  1999-12       Impact factor: 4.797

Review 7.  Global trends in breast cancer incidence and mortality.

Authors:  Peggy L Porter
Journal:  Salud Publica Mex       Date:  2009

8.  Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.

Authors:  M Mitui; S A Nahas; L T Du; Z Yang; C H Lai; K Nakamura; S Arroyo; S Scott; A Purayidom; P Concannon; M Lavin; R A Gatti
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

Review 9.  Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.

Authors:  N J H van Os; N Roeleveld; C M R Weemaes; M C J Jongmans; G O Janssens; A M R Taylor; N Hoogerbrugge; M A A P Willemsen
Journal:  Clin Genet       Date:  2016-01-20       Impact factor: 4.438

10.  Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank.

Authors:  Andrea V Margulis; Manel Pladevall; Nuria Riera-Guardia; Cristina Varas-Lorenzo; Lorna Hazell; Nancy D Berkman; Meera Viswanathan; Susana Perez-Gutthann
Journal:  Clin Epidemiol       Date:  2014-10-10       Impact factor: 4.790

View more
  5 in total

Review 1.  The role of epigenetic modifications in drug resistance and treatment of breast cancer.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Arash Kiani; Fateme Jalalifar; Parisa Osati; Mahsa Akbari Oryani; Fateh Shakeri; Farhad Nasirzadeh; Behman Khalesi; Mohsen Nabi-Afjadi; Hamidreza Zalpoor; Maysam Mard-Soltani; Zahra Payandeh
Journal:  Cell Mol Biol Lett       Date:  2022-06-28       Impact factor: 8.702

2.  Spontaneous Regression of Diffuse Large B-cell Lymphoma in a Patient with Ataxia-Telangiectasia.

Authors:  Roya Sherkat; Noushin Afshar Moghaddam; Nahid Reisi; Marzieh Rezaei
Journal:  Adv Biomed Res       Date:  2022-04-29

Review 3.  Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.

Authors:  Hamidreza Zalpoor; Mohsen Nabi-Afjadi; Razieh Forghaniesfidvajani; Chanour Tavakol; Faranak Farahighasreaboonasr; Farid Pakizeh; Vahid Ghobadi Dana; Farhad Seif
Journal:  Cell Mol Biol Lett       Date:  2022-07-26       Impact factor: 8.702

4.  RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity.

Authors:  Deanna V Maybee; Alexandra Maria Psaras; Tracy A Brooks; Mohammad A M Ali
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

Review 5.  The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice.

Authors:  Luigia Stefania Stucci; Valeria Internò; Marco Tucci; Martina Perrone; Francesco Mannavola; Raffaele Palmirotta; Camillo Porta
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.